The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014

• Citation: S.I. 2014/3271
• Sections: 4

Section 1 Citation and commencement

This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014 and comes into force on the twenty-eighth day after the day on which it is made.

Section 2 Amendments to the Misuse of Drugs Act 1971

The following amendments are made to Schedule 2 to the Misuse of Drugs Act 1971.

Section 3 Amendments to the Misuse of Drugs Act 1971

In paragraph 1(a) of Part 1 (which specifies the drugs which are subject to control under that Act as Class A drugs)—

(a) after “Trimeperidine” insert—

(6a R, 9 R )-4-acetyl -N,N -diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg ]quinoline-9-carboxamide (ALD-52).

(b) after “4-Cyano-1-methyl-4-phenyl-piperidine” insert—

3,4-dichloro- N -[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921);

(6aR,9R) R, 9 R )- N,N- diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg ]quinoline-9-carboxamide (AL-LAD);

(6aR,9R) R, 9 R ) -N,N- diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3 -fg ]quinoline-9-carboxamide (ETH-LAD);

(6aR,9R) R, 9 R )- N,N- diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg ]quinoline-9-carboxamide (PRO-LAD).

(c) after “ N,N- Diethyltryptamine” insert—

2,4-dimethylazetidinyl{(6a R, 9 R )-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg ]quinolin-9-yl}methanone (LSZ).

Section 4 Amendments to the Misuse of Drugs Act 1971

For paragraph 1(b) of Part 1, substitute—

(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

(i) by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;

(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;

(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;